AG真人官方

Reliance Global Group, Inc. (NASDAQ: RELI/RELIW) has divested its wholly owned Fortman Insurance Services business for $5.0 million in cash. The asset sale, executed on July 7 2025 and effective retroactively to July 1 2025, transfers Fortman鈥檚 book of business, renewal rights, trade names and other tangible & intangible assets to Fortman Insurance Agency, LLC. Excluded from the deal are pre-effective-date cash and certain other specified assets and liabilities.

Immediate balance-sheet impact: management used the proceeds to repay approximately 50% of the company鈥檚 outstanding debt, which it says lowers annual debt-service obligations by more than $1.8 million. The company disclosed these figures in press releases dated July 8 and July 10 2025 (filed as Exhibits 99.1 and 99.2).

Key contractual terms: the Asset Purchase Agreement (Exhibit 10.1) contains customary representations, warranties, indemnities and restrictive covenants. Closing occurred the same day the agreement was signed, suggesting no financing or regulatory contingencies.

Corporate governance update: on July 10 2025 the Board鈥檚 Compensation Committee increased CEO & Chairman Ezra Beyman鈥檚 annual base salary to $513,000 from $425,000 and approved a $593,000 cash bonus payable in 12 monthly installments starting July 2025.

Investor takeaways:

• The transaction converts a non-core agency asset into cash, materially de-levering the balance sheet and improving liquidity.
• An annual interest-expense reduction of >$1.8 million should flow directly to net income and cash flow, subject to the loss of Fortman鈥檚 future earnings, which the filing does not quantify.
• The sizable CEO compensation increase offsets a small portion of the interest savings and may raise governance questions, but does not negate the balance-sheet benefit.

Rockwell Medical, Inc. (RMTI) 鈥� Form 4/A amendment reports that Senior Vice President & Chief Financial Officer Jesse Neri sold 886 common shares on 01-Jul-2025 at a weighted-average price of $0.82 per share. The filing clarifies that the trade was executed pursuant to a Rule 10b5-1 trading plan adopted on 13-Dec-2024; this checkbox was inadvertently left blank in the original Form 4 filed 02-Jul-2025.

After the disposition, Neri directly owns 126,614 shares of RMTI. No derivative securities were bought or sold, and there are no other changes to his ownership stake.

The transaction represents roughly 0.7 % of the executive鈥檚 reported holdings and is immaterial relative to the company鈥檚 total shares outstanding. Because the sale was pre-arranged and the amendment is purely administrative, the filing carries limited fundamental significance but may still interest investors who monitor insider activity for sentiment cues.

Rockwell Medical, Inc. (RMTI) 鈥� Form 4/A amendment reports that Senior Vice President & Chief Financial Officer Jesse Neri sold 886 common shares on 01-Jul-2025 at a weighted-average price of $0.82 per share. The filing clarifies that the trade was executed pursuant to a Rule 10b5-1 trading plan adopted on 13-Dec-2024; this checkbox was inadvertently left blank in the original Form 4 filed 02-Jul-2025.

After the disposition, Neri directly owns 126,614 shares of RMTI. No derivative securities were bought or sold, and there are no other changes to his ownership stake.

The transaction represents roughly 0.7 % of the executive鈥檚 reported holdings and is immaterial relative to the company鈥檚 total shares outstanding. Because the sale was pre-arranged and the amendment is purely administrative, the filing carries limited fundamental significance but may still interest investors who monitor insider activity for sentiment cues.

Form 144 filing for LendingClub Corporation (LC) discloses that Chief Executive Officer Scott C. Sanborn intends to sell up to 10,500 common shares through Morgan Stanley Smith Barney on or after 3 July 2025. At the recent market price used in the filing, the transaction is valued at $130,725. The proposed sale represents roughly 0.01 % of the 114.2 million shares outstanding, thus having minimal dilutive impact.

Sanborn has already executed a series of Rule 10b5-1 programmed sales over the last three months, disposing of 31,500 shares in six equal blocks of 5,250 shares, generating aggregate gross proceeds of 鈮� $327,806. All shares being sold were originally acquired as restricted stock units on 25 Nov 2018.

Investors typically monitor Form 144 filings as an indicator of insider sentiment. While the dollar value is modest relative to Sanborn鈥檚 presumed total holdings and LC鈥檚 market capitalization, continued insider selling can create incremental supply and may be interpreted as a bearish signal if it persists or accelerates.

Worthington Steel, Inc. (WS) filed a Form 4 reporting that Chief Financial Officer Timothy A. Adams received an award of 9,485 restricted common shares on 06/27/2025 under the company鈥檚 2023 Long-Term Incentive Plan. The grant was made at $0 cost and will vest on 06/27/2028, three years after the grant date. After the transaction, Adams directly holds 45,069 common shares. No sales, derivative security exercises, or Rule 10b5-1 trading plans were disclosed. The filing represents routine executive equity compensation intended to align management and shareholder interests and is not expected to have a material near-term market impact.

Schedule 13G filing: On 27 June 2025 Akre Capital Management, LLC (ACM), Braddock Partners Offshore, LP and Braddock Capital Offshore, LLC jointly filed a Schedule 13G reporting a beneficial position in SOPHiA GENETICS SA (CUSIP H82027105).

The reporting persons collectively hold 3,719,140 ordinary shares, representing 5.6 % of the outstanding class. All voting and dispositive authority over the shares is shared; each entity reports zero sole voting or dispositive power and full shared power over the entire stake, triggering the 5 % disclosure threshold under Section 13(d).

ACM is organized in Delaware and operates as an investment adviser, while Braddock Partners Offshore, LP is a Cayman Islands limited partnership and Braddock Capital Offshore, LLC is a Delaware limited-liability company. The certification states that the securities were acquired 鈥榥ot for the purpose of or with the effect of changing or influencing the control鈥� of the issuer. No additional group members, subsidiary acquisitions, or 5 %-or-less disclaimers are indicated. An Exhibit A Joint Filing Agreement accompanies the submission.

Form 144 overview: SOPHiA GENETICS SA (ticker SOPH) has filed a Form 144 indicating the proposed sale of insider-held shares under Rule 144 of the Securities Act of 1933.

• Seller & relationship: The filing lists one unnamed insider ("person for whose account the securities are to be sold"). No further relationship data is provided in the snippet.
• Securities to be sold: 18,443 shares of common stock.
• Estimated market value: USD 56,066.72, implying an indicative share price of roughly USD 3.04.
• Broker: Morgan Stanley Smith Barney LLC, Executive Financial Services, New York.
• Planned trade date & venue: On or about 20 June 2025 on the NASDAQ.
• Shares outstanding: 66,687,085. The proposed sale represents approximately 0.028% of total shares outstanding鈥�not material from a dilution perspective.
• Source of shares: Restricted Stock Units acquired 18 June 2025; not a gift.
• Prior 3-month sales: The filer reports "Nothing to Report," indicating no other recent insider sales by this individual that must be aggregated.

Investor takeaway: The filing signals a routine disposal of a small block of shares by an insider. Given the limited size relative to total float and the absence of any cited adverse information, the market impact is likely negligible. Nevertheless, investors monitoring insider activity may note the transaction when evaluating sentiment and liquidity conditions.

SOPHiA GENETICS SA (SOPH) filed a Form 144 indicating that Ross J. Muken intends to sell up to 14,509 common shares through Morgan Stanley Smith Barney on or about 20 June 2025. At the most recent market price reflected in the filing, the shares have an aggregate value of $44,107.36. The company has 66,687,085 shares outstanding, meaning the proposed sale represents roughly 0.02 % of shares outstanding.

The filing also discloses that, under a Rule 10b5-1 trading plan, Muken has sold 14,542 shares in the prior three months for total gross proceeds of approximately $40,660. The current notice confirms the seller鈥檚 representation that no undisclosed material adverse information is known at the time of the planned sale.

Because the transaction size is modest relative to the company鈥檚 share count and is executed under a pre-arranged trading plan, the filing is routine and unlikely to have a material impact on SOPH鈥檚 capital structure or stock liquidity.